INTS
NASDAQ
$4.70
Intensity Therapeutics Inc (INTS)
Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. By focusing on enhancing the efficacy of immuno-oncology therapies and reducing systemic side effects, the company addresses critical unmet needs in the oncology market. With a robust research and development pipeline, Intensity Therapeutics aims to advance targeted therapies that empower the immune system to fight cancer more effectively, positioning itself as a leader in improving patient outcomes within a complex and rapidly evolving healthcare landscape.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $24.80 (+427.66%)
Market Cap
$12M
Free Cash Flow Yield
-73.76%
Beta (5Y)
-0.44
Price Chart
Valuation
Market Cap$12M
P/B1.32
Profitability
EBITDA-$11M
EPS-$5.95
Financial Health
Free Cash Flow Yield-73.76%
Growth & Risk
Beta (5Y)-0.44
Sharpe Ratio0.57